title: Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.
abstract: BACKGROUND
  The aim of this study was to evaluate the clinical outcomes and safety of daptomycin therapy in patients with serious Gram-positive infections.
  
  
  METHODS
  Patients were enrolled in the European Cubicin(®) Outcomes Registry and Experience (EU-CORE(SM)), a non-interventional, multicenter, observational registry. The real-world data were collected across 18 countries (Europe, Latin America, and Asia) for patients who had received at least one dose of daptomycin between January 2006 and April 2012. Two-year follow-up data were collected until 2014 for patients with endocarditis, intracardiac/intravascular device infection, osteomyelitis, or orthopedic device infection.
  
  
  RESULTS
  A total of 6075 patients were enrolled. The most common primary infections were complicated skin and soft tissue infection (31.7%) and bacteremia (20.7%). Staphylococcus aureus was the most frequently reported pathogen (42.9%; methicillin-resistant S. aureus [MRSA], 23.2%), followed by Staphylococcus epidermidis and other coagulase-negative staphylococci (CoNS, 28.5%). The most commonly prescribed dose of daptomycin was 6 mg/kg/day (43.6%), and the median duration of therapy was 11 (range 1-300) days. Overall clinical success rate was 80.5%, and was similar whether daptomycin was used as first-line (82.9%) or second-line (79.2%) therapy. Clinical success rates were high in patients with S. aureus (83.9%; MRSA 83.0%) and CoNS (including S. epidermidis, 82.5%) infections. The majority of patients with endocarditis or intracardiac/intravascular device infection (86.7%) or osteomyelitis/orthopedic device infection (85.9%) had a sustained response during the 2-year follow-up period. There were no new or unexpected safety findings.
  
  
  CONCLUSIONS
  Results from real-world clinical experience showed that daptomycin is a valuable therapeutic option in the management of various difficult-to-treat Gram-positive infections.
  
  
  BACKGROUND
  This study was funded by Novartis Pharma AG.
authors.affiliation: Darent Valley Hospital, Dartford, UK.
authors.forename: Armando
authors.initials: A
authors.lastname: Gonzalez-Ruiz
authors.forename: Panayiotis
authors.initials: P
authors.lastname: Gargalianos-Kakolyris
authors.forename: Artur
authors.initials: A
authors.lastname: Timerman
authors.forename: Jayanta
authors.initials: J
authors.lastname: Sarma
authors.forename: Víctor
authors.initials: V
authors.lastname: José González Ramallo
authors.forename: Kamel
authors.initials: K
authors.lastname: Bouylout
authors.forename: Uwe
authors.initials: U
authors.lastname: Trostmann
authors.forename: Rashidkhan
authors.initials: R
authors.lastname: Pathan
authors.forename: Kamal
authors.initials: K
authors.lastname: Hamed
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001208:Asia; D016470:Bacteremia / Q000188:drug therapy; D017576:Daptomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007843:Latin America; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D017192:Skin Diseases, Bacterial / Q000188:drug therapy; D018461:Soft Tissue Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin